Singular Genomics Systems Inc
NASDAQ:OMIC
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
5.65
23.3
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one OMIC stock under the Base Case scenario is 74.41 USD. Compared to the current market price of 22.97 USD, Singular Genomics Systems Inc is Undervalued by 69%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Singular Genomics Systems Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for OMIC cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Singular Genomics Systems Inc
Balance Sheet Decomposition
Singular Genomics Systems Inc
Current Assets | 148.7m |
Cash & Short-Term Investments | 133.4m |
Receivables | 440k |
Other Current Assets | 14.9m |
Non-Current Assets | 71.3m |
PP&E | 69.6m |
Other Non-Current Assets | 1.7m |
Current Liabilities | 16.9m |
Accounts Payable | 1.5m |
Accrued Liabilities | 11.1m |
Other Current Liabilities | 4.3m |
Non-Current Liabilities | 65.3m |
Long-Term Debt | 6.4m |
Other Non-Current Liabilities | 59m |
Earnings Waterfall
Singular Genomics Systems Inc
Revenue
|
2.7m
USD
|
Cost of Revenue
|
-3.8m
USD
|
Gross Profit
|
-1.1m
USD
|
Operating Expenses
|
-98.3m
USD
|
Operating Income
|
-99.5m
USD
|
Other Expenses
|
7.6m
USD
|
Net Income
|
-91.9m
USD
|
Free Cash Flow Analysis
Singular Genomics Systems Inc
USD | |
Free Cash Flow | USD |
In Q2 2024, Singular Genomics focused on developing the G4X Spatial Sequencer, offering advanced readouts and improved throughput. Revenue reached $0.7 million, including sales of two G4 instruments. Despite enhancements, the company reported a net loss of $21.3 million. Cash reserves stood at $133.2 million, with a cash burn of $17.5 million, reduced from previous quarters. They plan an early access program for G4X by year-end 2024, with a commercial launch in mid-2025, aiming to address spatial biology needs and expand their market.
What is Earnings Call?
OMIC Profitability Score
Profitability Due Diligence
Singular Genomics Systems Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Singular Genomics Systems Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
OMIC Solvency Score
Solvency Due Diligence
Singular Genomics Systems Inc's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Score
Singular Genomics Systems Inc's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
OMIC Price Targets Summary
Singular Genomics Systems Inc
According to Wall Street analysts, the average 1-year price target for OMIC is 9.66 USD with a low forecast of 6.57 USD and a high forecast of 13.07 USD.
Dividends
Current shareholder yield for OMIC is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
OMIC Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Singular Genomics Systems, Inc. engages in the development and commercialization of proprietary sequencing solutions. The company is headquartered in La Jolla, California and currently employs 221 full-time employees. The company went IPO on 2021-05-27. The firm has developed an NGS technology or sequencing engine. The company is developing two integrated solutions that are built to target specific applications. The firm's first integrated solution is targeted at the NGS market and comprises an instrument and an associated menu of consumable kits, which is collectively referred as G4 Integrated Solution. The G4 Instrument is a sequencer designed to produce accurate genetic sequencing results. Its second integrated solution in development comprises an instrument and an associated menu of consumable kits, which is collectively referred as PX Integrated Solution. The PX Integrated Solution combines single cell analysis, spatial analysis, genomics and proteomics in one integrated instrument providing a multiomics solution.
Contact
IPO
Employees
Officers
The intrinsic value of one OMIC stock under the Base Case scenario is 74.41 USD.
Compared to the current market price of 22.97 USD, Singular Genomics Systems Inc is Undervalued by 69%.